Remicade, long J&J’s top-selling drug, is approved for treating rheumatoid arthritis, psoriasis, colitis and other immune system disorders. J&J said it will compete with Inflectra “through a variety of innovative contracting options, discounts and rebates to payers, providers and pharmacy benefit managers” to keep Remicade affordable for patients....